The use of traditional chemotherapeutic drugs plus bevacizumab, a targeted drug that neutralized the vascular endothelial growth factor, largely prolongs the median PFS of ovarian cancer patients [24]. The gene discussed is VEGFA; the disease is ovarian carcinoma.